Trial Profile
Double-blind Randomized Placebo-controlled Study to Evaluate the Efficacy and Safety of Intermittent, Long-term Administration of Levosimendan in Patients With Advanced Heart Failure.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Levosimendan (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Acronyms LAICA
- 12 Dec 2015 Status changed from recruiting to discontinued, according to European Clinical Trials Database record.
- 17 Sep 2013 Planned end date changed from 21 Sep 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 17 Jan 2012 Planned End Date changed from 1 Nov 2011 to 21 Sep 2013.